Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 7
Panelists discuss how the evolving treatment landscape, including CAR T-cell therapy and bispecifics, has made it possible to offer cellular therapies like cilta-cel as early as second-line treatment for eligible patients.
Incorporating CAR T in Early Relapsed Multiple Myeloma
CAR T-cell therapies are transforming the treatment paradigm in relapsed/refractory multiple myeloma. Recent approvals now allow ide-cel and cilta-cel to be used in earlier lines of therapy, particularly in patients who are refractory to lenalidomide.
These approvals open up new opportunities for early intervention, especially for patients with high functional risk or rapid relapse after transplant. Selecting patients with controlled disease and good performance status remains critical to optimizing outcomes and minimizing toxicity.
Clinicians increasingly favor offering CAR T-cell therapy in the second line to eligible patients rather than delaying until later relapse. This shift helps avoid attrition and ensures patients receive high-impact treatment when they are most likely to benefit.